Cell death constitutes a critical component of the pathophysiology of cardiovascular diseases. A growing array of non-apoptotic forms of regulated cell death (RCD)-such as necroptosis, ferroptosis, pyroptosis, and cuproptosis-has been identified and is intimately linked to various cardiovascular conditions. These forms of RCD are governed by genetically programmed mechanisms within the cell, with epigenetic modifications being a common and crucial regulatory method. Such modifications include DNA methylation, RNA methylation, histone methylation, histone acetylation, and non-coding RNAs. This review recaps the roles of DNA methylation, RNA methylation, histone modifications, and non-coding RNAs in cardiovascular diseases, as well as the mechanisms by which epigenetic modifications regulate key proteins involved in cell death. Furthermore, we systematically catalog the existing epigenetic pharmacological agents targeting novel forms of RCD and their mechanisms of action in cardiovascular diseases. This article aims to underscore the pivotal role of epigenetic modifications in precisely regulating specific pathways of novel RCD in cardiovascular diseases, thus offering potential new therapeutic avenues that may prove more effective and safer than traditional treatments.
Keyphrases
- dna methylation
- cell death
- cardiovascular disease
- genome wide
- gene expression
- cell cycle arrest
- cardiovascular events
- transcription factor
- cardiovascular risk factors
- type diabetes
- copy number
- nlrp inflammasome
- stem cells
- single cell
- cell therapy
- drug delivery
- high throughput
- cancer therapy
- risk assessment
- metabolic syndrome
- signaling pathway
- histone deacetylase
- mass spectrometry
- cell proliferation
- human health